Moderna cuts Ares loan rate, girds for $4B yearly spend through 2030
What's the deal? Moderna has secured better terms on its $1.5 billion credit facility with Ares ManagementDealroom has a profile for this one. Try Dealroom →, pushing the maturity out one year to 2031 and cutting the interest rate on drawn funds by 75 basis points. The vaccine and oncology developer disclosed the change alongside its 2026 analyst day. It frames the move as added flexibility to fund a heavy multi-year spending plan.
Why now? Moderna laid out cash costs of roughly $4 billion for 2027 and $4 billion to $4.5 billion annually through 2030, driven mainly by oncology. That exceeds the midpoint of the $3.5 billion to $3.9 billion range it set in January. Formal 2027 revenue guidance won't come until the fourth-quarter earnings call.
The numbers: Moderna raised its 2026 revenue growth outlook to 15% to 25%, up from an earlier forecast of up to 10%. Third-quarter revenue hit $1.3 billion, up 29% year on year, with GAAP net profit of $162 million, or $0.38 per diluted share. It expects about $9 billion in total liquidity at year-end, including $900 million of undrawn borrowing capacity available through 2029.
What's the endgame? Chief executive officer Stéphane Bancel said the company is "now advancing intismeran toward potential commercialization" following positive Phase 3 results in adjuvant melanoma. The personalized cancer vaccine, developed with Merck, could reach a filing and approval in 2027. Oncology sits at the heart of the spending programme.
What could go wrong? The cost framework locks up capital for years, and if revenue lags, it would press harder on financial flexibility. Shares fell 6.97% to $231.35 on analyst day, as the $4 billion plan landed without 2027 revenue guidance. Recent growth has leaned heavily on international COVID-vaccine demand.
The signal: Cheaper credit buys Moderna time, but the investment case still rests on whether oncology and new products can turn spending into durable growth. The next checkpoint is the fourth-quarter 2026 results, when the company will present formal 2027 guidance against its announced cost base.
Read more: ad-hoc-news.de, Business Insider
Image credit: Generated with Gemini
